TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The companies will work with investigators to share the results with the scientific community
Marks the World Head & Neck Cancer Day at the OCTF Conference
From cancer research to diagnostic solutions
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Subscribe To Our Newsletter & Stay Updated
